Human Monoclonal Antibodies to Programmed Death 1(PD-1) and Methods for Treating Cancer Using ANTI-PD-1 Antibodies Alone or in Combination with Other Immunotherapeutics
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/JP2006/309606, filed May 2, 2006. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,441,655 | Monoclonal Antibodies to Programmed Death 1 (PD-1) In force · High confidence UsedRemaining | E. R. Squibb & Sons, L.L.C. | In force | High confidence | ||
| US 8,779,105 | Monoclonal Antibodies to Programmed Death 1 (PD-1) In force · High confidence | E. R. Squibb & Sons, L.L.C. | In force | High confidence | ||
| US 8,008,449 | Human Monoclonal Antibodies to Programmed Death 1(PD-1) and Methods for Treating Cancer Using ANTI-PD-1 Antibodies Alone or in Combination with Other Immunotherapeutics In force · High confidence | E. R. Squibb & Sons, L.L.C. | In force | High confidence | ||
| US 9,084,776 | Methods for Treating Cancer Using ANTI-PD-1 Antibodies Term ended Term ended May 2, 2026 · High confidence | E. R. Squibb & Sons, L.L.C. | Term ended | Term ended May 2, 2026 | High confidence | |
| US 9,358,289 | Methods for Treating Cancer Using ANTI-PD-1 Antibodies in Combination with ANTI-CTLA-4 Antibodies Term ended Term ended May 2, 2026 · High confidence | E. R. Squibb & Sons, L.L.C. | Term ended | Term ended May 2, 2026 | High confidence | |
| US 9,492,540 | Methods for Treating Cancer Using ANTI-PD-1 Antibodies Term ended Term ended May 2, 2026 · High confidence | E. R. Squibb & Sons, L.L.C. | Term ended | Term ended May 2, 2026 | High confidence | |
| US 9,387,247 | Monoclonal Antibodies to Programmed Death 1 (PD-1) Term ended Term ended Oct 24, 2026 · High confidence | E. R. Squibb & Sons, L.L.C. | Term ended | Term ended Oct 24, 2026 | High confidence | |
| US 9,492,539 | Monoclonal Antibodies to Programmed Death 1 (PD-1) Term ended Term ended Oct 24, 2026 · High confidence | E. R. Squibb & Sons, L.L.C. | Term ended | Term ended Oct 24, 2026 | High confidence | |
| Application 16/600,272 | Monoclonal Antibodies to Programmed Death 1 (PD-1) Abandoned Abandoned Mar 10, 2023 | E. R. Squibb & Sons, L.L.C. | Abandoned | Abandoned Mar 10, 2023 | ||
| Application 18/167,012 | Monoclonal Antibodies to Programmed Death 1 (PD-1) Abandoned Abandoned Jun 23, 2026 | E.R. Squibb & Sons, L.L.C. | Abandoned | Abandoned Jun 23, 2026 |
10 of 10 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by E R Squibb and Sons LLC.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.